SuperworthHeron Therapeutics shares outstanding HRTX
Diluted shares outstanding, averaged over each quarter, from 2012.
- Latest quarter, to Jun 30, 2026
- 190.3M
- On a year earlier
- +23.6%
- more shares
Heron Therapeutics had 190.3M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 23.6% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 188M | +23% |
| FY2024 | 153.2M | +1% |
| FY2023 | 151.2M | +27% |
| FY2022 | 119M | +17% |
| FY2021 | 102M | +12% |
| FY2020 | 91.1M | +2% |
| FY2019 | 89.1M | +14% |
| FY2018 | 78.1M | +36% |
| FY2017 | 57.6M | +47% |
| FY2016 | 39.3M | +9% |
| FY2015 | 36M | +23% |
| FY2014 | 29.2M | +56% |
| FY2013 | 18.7M | +24% |
| FY2012 | 15.1M | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 190.3M | +24% | |
| Q1 FY26 | 189.6M | −4% | |
| Q4 FY25 | 188M | +23% | |
| Q3 FY25 | 170.3M | +11% | |
| Q2 FY25 | 154M | +1% | |
| Q1 FY25 | 196.9M | +30% | |
| Q4 FY24 | 153.2M | +1% | |
| Q3 FY24 | 152.8M | +5% | |
| Q2 FY24 | 152.3M | +27% | |
| Q1 FY24 | 151.2M | +27% | |
| Q4 FY23 | 151.2M | +27% | |
| Q3 FY23 | 145M | +30% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Heron Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.